Nurhan Önal KALKAN, Mustafa ÖZTÜRK

The Effects of Proton Pump Inhibitors For Dispeptic Complaints In Patients With Nonalcoholic Steatohepatitis

As the most common liver disease in recent years, nonalcoholic fatty liver disease (NAFLD) has gained great importance. In recent years, a close relationship with insulin resistance has been shown in the pathogenesis of NAFLD and its severe form, NASH. This study aimed to observe the effects of proton pump inhibitors (PPIs) on insulin resistance and hepatosteatosis by causing hypergastrinemia. Forty-two patients diagnosed with steatohepatitis were included in the study. Seventeen of the 42 patients were followed up with dietary therapy alone, and 25 were followed up with diet+PPI for 2 months due to accompanying dyspeptic complaints. Biochemical and anthropometric measurements of the patients were made before and after the treatment. Levels of the following parameters decreased significantly after treatment in cases followed only with diet: total cholesterol (p=0.009), low-density lipoprotein (LDL) (p=0.007), weight (p=0.004), waist circumference (p=0.006), and body mass index (BMI) (p=0.026). Whereas, there was a significant decrease in the levels of alanine transaminase (ALT) (p=0.005), aspartate transaminase (AST) (p=0.009), total cholesterol (p=0.020), low-density lipoprotein (LDL) (p=0.031), and waist circumference (p=0.008) after treatment with diet+PPI. After two months, the increase in the mean insulin resistance levels (HOMA-IR) in the diet group was significantly higher than the increase of mean HOMA-IR levels in the diet+PPI group (p=0.02). In conclusion, a significant improvement in liver enzymes was observed in patients with Nonalcoholic steatohepatitis with 2 months of pantoprazole treatment added to dietary management.

PDF

___

1. Vlad R, Frederic C, Agnes H, Sophie G, Phillipe G, Eric B. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Clin Gastroenterology 2005; 128: 1898-1906
2. Sargin M, Uygur-Bayramiçli O, Sargin H, Orbay E, Yayla A. Association of nonalcoholic fatty liver disease with insulin resistance. Is OGTT indicated in nonalcoholic fatty liver disease? J Clin Gastroenterol 2003; 37: 399-402.
3. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology. 1990; 12(5): 1106-10
4. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin. Hepatology 2004; 40: 46-54 .
5. Lisa B and Van Wagner, The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis Therapy Advances in Gastoenterology 2011; 4: 249-263.
6. Lind T, Cederberg C, Forssell H, Olausson M and Olbe L. Relationship between reduction of gastric acid secretion and plasma gastrin concentration during omeprazole treatment. Scand. J. Gastroenterol 1988; 23: 1259-1266.
7. Rooman I, Lardon J, Bouwens L Gastrin stimulates beta cell neogenesis and increases islet mass from transdifferentiated but not from normal exocrine pancreas tissue. Diabetes 2002; 51: 686-690.
8. Malnick SDH, Beergabel M, Khobler H. Nonalcoholic fatty Liver: a common manifestation of metabolic disorder. Q J med 2003; 96: 699-709.
9. Parola M, Robino G, Oxidative stress-related molecules and liver fibrosis. Hepatol 2001; 35: 297-306.
10. Goldstein BJ, Mahadev KWuX. Redox paradox: insulin action is facilitated by insulin stimulated reactive oxygen specific with multiple potential signaling targets. Diabetes 2005; 54: 311-321.
11. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 450-455.
12. Gurbuz AK, Ozel MA, Yazgan Y, Alp Gunay, Polat T. Does eradication of helicobacter pylori reduce hypergastrinemia during long term therapy with proton pumps inhibitors. The East African Medical Journal 2003; 80: 150-153.
13. Dammann H and Burkhardt F. Influence of pantoprazole 40 mg and omeprazole 20 mg on meal-stimulated gastric acid secretion Gastroenterology 1998; 114: 98.
14. Vilsboll T and Holst J. Incretins, insulin secretion and Type 2 diabetes mellitus. Diabetologia 2004; 47: 357-366.